References
- 1. Sjöberg F, Singer M. The medical use of oxygen: a time for critical reappraisal. J Intern Med. 2013 Dec;274(6):505-28. doi: 10.1111/joim.12139;10.1111/joim.12139
- 2. Yilmaz N. Relationship between paraoxonase and homocysteine: crossroads of oxidative diseases. Arch Med Sci. 2012 Feb 29;8(1):138-53. doi: 10.5114/aoms.2012.27294;
- 3. Allen MW, Golembe E, Gorenstein S, Butler GJ. Protective effects of hyperbaric oxygen therapy (HBO2) in cardiac care-a proposal to conduct a study into the effects of hyperbaric preconditioning in elective coronary artery bypass graft surgery (CABG). Undersea Hyperb Med.2015 Mar-Apr; 42.107-114. doi:10.2214/ajr.151.5.1003;10.2214/ajr.151.5.1003
- 4. Davalli P, Mitic T, Caporali A, Lauriola A, D’Arca D. ROS, cell senescence, and novel molecular mechanisms in aging and age-related diseases. Oxid Med Cell Longev. 2016;2016:3565127. doi: 10.1155/2016/3565127;10.1155/2016/3565127
- 5. Rahal A, Kumar A, Singh V et al. Oxidative stress, prooxidants, and antioxidants: the interplay. Biomed Res Int. 2014;2014:761264. doi: 10.1155/2014/761264;
- 6. Dennog C, Hartmann A, Frey G, Speit G. Detection of DNA damage after hyperbaric oxygen (HBO2) therapy. Mutagenesis. 1996 Nov;11(6):605-609. doi:10.10193;8962431
- 7. Narkowicz CK, Vial JH, McCartney PW. Hyperbaric oxygen therapy increases free radical levels in the blood of humans. Free Radic Res Commun. 1993;19(2):71-80. PMID: 8225040 doi:10.3109/10715769309056501;10.3109/10715769309056501
- 8. Simsek K, Ozler M, Ucar E, et al. Pressure-related effects of hyperbaric oxygen exposure on oxidation products and antioxidant enzymes in the rat lung. J Exp Integr Med. 2011; 1(1):37-42 doi:10.5455/jeim.130111.or.003;
- 9. Simsek K, Ozler M, Yildirim AO et al. Evaluation of the oxidative effect of long term repetitive hyperbaric oxygen exposures on different brain regions of rats. Scientific World Journal. 2012;2012:849183. doi:10.1100/2012/849183;
- 10. Eren E, Ellidag HY, Aydin O, Yilmaz N. HDL functionality and crystal-based sterile inflammation in atherosclerosis. Clin Chim Acta. 2015 Jan 15;439,18-23. doi: 10.1016/j.cca.2014.09.024;
- 11. McGarry T, Biniecka M, Veale DJ, Fearon U. Hypoxia, oxidative stress and inflammation. Free Radic Biol Med. 2018 Mar 27. pii: S0891-5849(18)30145-X. doi: 10.1016/j.freeradbiomed.2018.03.042;10.1016/j.freeradbiomed.2018.03.042
- 12. Tsoupras A, Lordan R, Zabetakis I. Inflammation, not cholesterol, is a cause of chronic disease. Nutrients. 2018 May 12;10(5). pii: E604. doi: 10.3390/nu10050604;
- 13. Tsoupras AB, Iatrou C, Frangia C, Demopoulos CA. The implication of platelet activating factor in cancer growth and metastasis: potent beneficial role of PAF-inhibitors and antioxidants. Infect Disord Drug Targets. 2009 Aug;9(4):390-9. doi:10.2174/187152609788922555;10.2174/187152609788922555
- 14. Palur Ramakrishnan AV, Varghese TP, Vanapalli S, Nair NK, Mingate MD. Platelet activating factor: A potential biomarker in acute coronary syndrome? Cardiovasc Ther. 2017 Feb;35(1):64-70. doi: 10.1111/1755-5922.12233;10.1111/1755-5922.12233
- 15. Nakamura T, Murata T. Regulation of vascular permeability in anaphylaxis. Br J Pharmacol. 2018 Jul;175(13):2538-2542 doi: 10.1111/bph.14332;10.1111/bph.14332
- 16. Bulger EM, Maier RV. Lipid mediators in the pathophysiology of critical illness. Crit Care Med. 2000 Apr;28(4 Suppl):N27-36 doi:10.1097/00003246-200004001-00004;10.1097/00003246-200004001-00004
- 17. Papakonstantinou VD, Lagopati N, Tsilibary EC, Demopoulos CA, Philippopoulos AI. A review on platelet activating factor inhibitors: could a new class of potent metal-based anti-inflammatory drugs induce anticancer properties? Bioinorg Chem Appl. 2017;2017:6947034, doi: 10.1155/2017/6947034;10.1155/2017/6947034
- 18. Gao ZX, Rao J, Li YH. Hyperbaric oxygen preconditioning improves postoperative cognitive dysfunction by reducing oxidant stress and inflammation. Neural Regen Res. 2017 Feb;12(2):329-336 doi: 10.4103/1673-5374.200816;10.4103/1673-5374.200816
- 19. Yildirim G, Baştuğ M, Akçil IE, Fiçicilar H, Koç E, Zaloğlu N. Does the plateletactivating factor affect the antioxidant defense system? The possible role of hyperbaric oxygenation. Biol Trace Elem Res. 2000 Winter;78(1-3):7-12. doi:10,1385/BTER:78:1-3:7;
- 20. Yildirim G, Koç E, Baştug M, Fiçicilar H, Akçil IE, Zaloglu N. Effects of plateletactivating factor and hyperbaric oxygenation on antioxidant defense and duodenal contractility. Undersea Hyperb Med. 2000 Fall;27(3):155-8.doi.org/10.22462/01.02.2018.6;
- 21. Eren E, Yilmaz N, Aydin O. High density lipoprotein and it’s dysfunction. Open Biochem J. 2012;6.78-93 doi: 10,2174/1874091X01206010078;
- 22. Keskin K, Kilci H, Aksan G, et al. Serum oxidized low-density lipoprotein level as a marker of oxidative stress in patients undergoing hyperbaric oxygen therapy. Turk Kardiyol Dern Ars. 2017 Sep;45(6):533-537. doi: 10.5543/tkda.2017.28302;10.5543/tkda.2017.28302
- 23. Matzi V, Greilberger JF, Lindenmann J, et al. Application of hyperbaric oxygen reduce oxidative damage of plasmatic carbonyl proteins and 8-OHdG by activating glutathion peroxidase. Clin Lab. 2015;61(5-6):587-93.doi:10.7754/Clin.Lab.2014.140929;
- 24. Kudchodkar B, Jones H, Simecka J, Dory L. Hyperbaric oxygen treatment attenuates the pro-inflammatory and immune responses in apolipoprotein E knockout mice. Clin Immunol. 2008 Sep;128(3):435-41. doi: 10.1016/j.clim.2008.05.004; Epub 2008 Jul 2;10.1016/j.clim.2008.05.004;Epub2008Jul2
- 25. Kudchodkar BJ, Pierce A, Dory L. Chronic hyperbaric oxygen treatment elicits an antioxidant response and attenuates atherosclerosis in apoE knockout mice. Atherosclerosis. 2007 Jul;193(1):28-35. doi:10.1016/j.atherosclerosis.2006.08.018;10.1016/j.atherosclerosis.2006.08.018
- 26. Snyder F.Platelet-activating factor and related acetylated lipids as potent biologically active cellular mediators. Am J Physiol. 1990 Nov;259 (5 Pt 1):C697-708.doi:10.1152/ajpcell.1990.259.5.C697;10.1152/ajpcell.1990.259.5.697